PET-CT Scanner

What is a PET-CT scan and how does it work?

PET (positron emission tomography) traces a tiny amount of radioactively labelled sugar — FDG — injected into a vein. Because many cancer cells consume glucose faster than the tissue around them, they light up on the PET image. CT (computed tomography), acquired in the same session on the same machine, supplies the anatomical map. The scanner fuses the two: activity from PET, address from CT. Other tracers extend the method beyond sugar — prostate-specific tracers such as PSMA, and receptor tracers such as DOTA compounds for neuroendocrine tumours — each chosen by the nuclear medicine physician for the question being asked.

What a PET-CT scan shows — and is used for

The scan’s four classic jobs: staging a newly diagnosed cancer — one whole-body study showing whether disease has spread, and where; assessing treatment response — comparing activity before and after chemotherapy or radiotherapy, often earlier and more truthfully than size changes alone; hunting recurrence when a tumour marker rises but conventional imaging sees nothing; and characterising ambiguous findings, where activity helps separate the suspicious from the innocent. Beyond oncology, PET-CT contributes to selected cardiac viability and inflammation questions — your physician defines the indication, because the tracer and protocol follow from it.

The scan: preparation and what actually happens

Preparation protects the image: fasting for several hours beforehand, avoiding strenuous exercise the previous day, and — for diabetic patients — glucose management coordinated in advance, because sugar in the blood competes with the tracer. On the day: a small injection, then a quiet resting hour while the tracer distributes (resting genuinely matters — active muscles steal signal), then the scan itself, typically 20–30 minutes on the couch. The whole visit spans two to three hours. Afterwards you may resume normal life; drinking water helps clear the tracer, and close, prolonged contact with pregnant women and small children is limited for the rest of the day as a courtesy of caution.

PET-CT results: how they are read

The report describes where activity concentrates and how intensely — often expressed as SUV values — against the anatomical background. Two honest truths about interpretation: not everything bright is cancer (infection, inflammation and healing tissue also consume sugar), and not every cancer is bright (some low-grade tumours sip rather than gulp). This is precisely why PET-CT reports at Acibadem are read by nuclear medicine physicians and then weighed in tumour boards alongside pathology and the clinical story — the scan informs the decision; it does not make it alone.

Radiation, safety and honest limits

A PET-CT involves a real but managed radiation dose — from both the tracer and the CT — justified when the answer changes treatment, and minimised by modern scanners and protocols. The examination is generally avoided in pregnancy, and breastfeeding requires a planned pause; tell the team beforehand. The tracer itself causes no side effects patients feel — it is a sugar, not a drug.

What determines the cost of a PET-CT scan?

“PET scan cost” is one of the most-searched phrases around this technology, and the honest answer is that price varies enormously by country, tracer and setting. The real variables: which tracer the question needs (FDG versus speciality tracers like PSMA), whether the study is part of a staging work-up read into a tumour board, and insurer or national-coverage arrangements. At Acibadem, planned imaging follows the group’s written-estimate practice — the cost is stated before the appointment — and for international patients the scan is usually scheduled within a records-first plan so one visit covers imaging and the consultation that acts on it.

PET-CT at Acibadem

PET-CT operates within the group’s nuclear medicine departments, with corporate-verified installations at campuses including Altunizade in Istanbul, City Clinic Mladost in Sofia and Sistina in Skopje. Reports flow into the group’s tumour-board oncology, and images travel in your file — readable at every campus, comparable scan to scan.

PET-CT cancer by cancer: where it changes decisions

The scan’s value is easiest to see in specifics. In lymphoma, PET-CT is woven into the standard of care — staging at diagnosis, and the interim scan whose Deauville score can escalate or de-escalate chemotherapy mid-course. In lung cancer it polices the mediastinum and hunts distant spread before surgery is promised, and it flags which nodes EBUS should sample. In melanoma, head-and-neck, oesophageal and cervical cancers, whole-body staging routinely redraws maps that CT alone had settled. In colorectal cancer it earns its place when markers rise but scans stay silent, and before liver-metastasis surgery — the operation nobody wants to perform twice. Prostate cancer belongs increasingly to PSMA tracers, which see recurrence at PSA levels conventional imaging cannot touch; neuroendocrine tumours to DOTA tracers reading their receptors. And everywhere, the response question — is this treatment working? — is answered in metabolic weeks rather than anatomical months. None of this replaces the tumour board; it feeds it the map.

What separates a good PET-CT from a scan

Three quiet factors decide quality. Preparation discipline: glucose control, genuine rest during uptake, warmth (shivering muscles and brown fat both light up and can mimic or mask disease) — the protocols exist because physics punishes shortcuts. Reading depth: a nuclear medicine physician who knows the pitfalls — post-treatment inflammation, physiological uptake patterns, the artefacts of motion and blood sugar — separates signal from story. Continuity: response assessment is a comparison, and comparisons are honest when acquisition and platform match scan to scan, which is why serial studies belong in one system. At Acibadem all three are house rules, and every oncological read lands in a file the group’s tumour boards and every campus can open.